Select a Sector or Industry
Return on Equity Rankings for Drug Manufacturers - Major Industry
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
| Rank | Symbol | Company |
Return on Equity
|
Pro Rating
|
|---|---|---|---|---|
| 1 | GSK | GlaxoSmithKline | 54.98% | Go Pro |
| 2 | AZN | AstraZeneca Group | 37.69% | Go Pro |
| 3 | LLY | Eli Lilly and Company | 30.04% | Go Pro |
| 4 | BMY | Bristol-Myers Squibb Company | 23.72% | Go Pro |
| 5 | ABT | Abbott Laboratories | 20.27% | Go Pro |
| 6 | SKBI | Skystar Bio - Pharmaceutical Company | 17.28% | Go Pro |
| 7 | JNJ | Johnson & Johnson | 16.73% | Go Pro |
| 8 | NVS | Novartis | 13.19% | Go Pro |
| 9 | CPHI | China Pharma | 12.45% | Go Pro |
| 10 | MRK | Merck | 12.13% | Go Pro |
| 11 | IPXL | Impax Laboratories | 11.05% | Go Pro |
| 12 | PFE | Pfizer | 10.98% | Go Pro |
| 13 | KUN | China Shenghuo Pharmaceutical | 5.43% | Go Pro |
| 14 | ASTX | Astex Pharmaceuticals | 2.31% | Go Pro |
| 15 | AXN | Aoxing Pharmaceutical Company | -21.80% | Go Pro |
| 16 | RIGL | Rigel Pharmaceuticals | -39.01% | Go Pro |
| 17 | ECYT | Endocyte | -44.29% | Go Pro |
| 18 | ALIM | Alimera Sciences | -71.90% | Go Pro |
| 19 | AEGR | Aegerion Pharmaceuticals | -77.46% | Go Pro |
| 20 | KERX | Keryx Biopharmaceuticals | -98.24% | Go Pro |
| 21 | PCRX | Pacira Pharmaceuticals | -148.1% | Go Pro |
| 22 | ANTH | Anthera Pharmaceuticals | -274.9% | Go Pro |
| 23 | ACRX | AcelRx Pharmaceuticals | -284.9% | Go Pro |
| 24 | ZGNX | Zogenix | -867.8% | Go Pro |
